Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cosmo Pharmaceuticals SpA Issues Patent Application for Methylene Blue MMX


Tuesday, 8 Oct 2013 01:00am EDT 

Cosmo Pharmaceuticals SpA announced that the USPTO has issued its patent application for Methylene Blue MMX under reference US 8,545,811. This patent was filed in 2010. Following the approval of the special protocol assessment (SPA) by the FDA, the European Medicines Agency (EMA) has approved the clinical trial protocol and confirmed the application of the centralized procedure for registration. The phase III clinical trial is scheduled to start in November treating approximately 1270 patients in 14 the United States, and European Union hospitals. 

Company Quote

38.7
0.3 +0.78%
4 Mar 2013